In adults, this includes the treatment of obesity with a BMI of 30 or higher, as well as overweight with a BMI of 27 or higher if at least one weight-related comorbidity is present
Weight loss drug semaglutide approved for NHS use Published A weight loss jab that has gained popularity in the US has been approved for use by the NHS in England
To view a copy of this licence, visit About this article Cite this article Havranek, B., Loh, R., Torre, B
How are Klow and Glow tested
This is evidence-based guidance to help clinicians and patients align dietary practices with pharmacologic therapy, ensuring improved metabolic outcomes, greater long-term weight loss success, and enhanced overall well-being.
Blood sugar regulation: Retatrutide can maintain consistent blood sugar levels throughout the day by activation of GLP-1 and GIP receptors